Cupid Co-Chairman Predicts FY27 Revenue At ₹725-750 Crore, Net Profit At ₹210-225 Crore

Market snapshot: Cupid is experiencing robust operational momentum as its leadership projects upgraded financial guidance for the current fiscal year. The company's recent quarterly performance showcases strong demand across its international B2B segment, while its long-term strategic focus shifts toward premium domestic retail and medical diagnostics.

Data Snapshot

• Consolidated revenue from operations surged 159% YoY to ₹154.72 crore in Q1 FY27, compared to ₹59.7 crore in Q1 FY26.
• Consolidated net profit grew nearly threefold YoY to ₹44.15 crore in Q1 FY27 from ₹15 crore in Q1 FY26.
• Cupid is expanding its FMCG footprint with a planned strategic investment of ₹331.53 crore in Baazar Style Retail Limited, with ₹82.88 crore already deployed as of May 2026.

What's Changed

• FY27 financial guidance has been upgraded from the initial target of ₹600 crore revenue and ₹180 crore net profit set in May 2026 to ₹725-750 crore revenue and ₹210-225 crore net profit.
• Q1 FY27 consolidated revenue reached ₹154.72 crore, representing 159% YoY growth and indicating that the company is on track to surpass previous full-year benchmarks.
• EBITDA margin reached 39% in Q1 FY27, up 1,127 basis points YoY, supported by a 10% price increase implemented across its export portfolio.

Key Takeaways

• Strong international B2B healthcare procurement and global government tenders continue to provide a high-margin order backlog.
• Strategic investment of ₹331.53 crore in Baazar Style Retail Limited unlocks a direct channel of 250+ retail stores for Cupid's FMCG wellness portfolio.
• Development of premium Nitrile Female Condoms positions Cupid as the sole manufacturer in India with dual-polymer (latex and nitrile) capabilities.

SAHI Perspective

The upgraded guidance reflects a rapid transition from a tender-reliant business model to an integrated FMCG and premium wellness brand. Operating leverage from the expanded Nasik manufacturing facility and favorable pricing power in export markets are feeding straight to the bottom line, which is visible in the robust net profit target of ₹210-225 crore for FY27.

Market Implications

The combination of aggressive insider buying by CMD Aditya Halwasiya and upgraded near-term guidance reinforces market confidence. However, with the stock trading at a historically high valuation multiple, execution consistency across its newly launched diagnostics and domestic FMCG divisions will be critical to sustain this premium.

Trading Signals

Market Bias: Bullish

Upgraded FY27 guidance of ₹725-750 crore revenue and ₹210-225 crore net profit represents strong fundamental momentum, backed by a threefold surge in Q1 FY27 profits to ₹44.15 crore.

Overweight: FMCG, Healthcare, Diagnostics

Trigger Factors:

• Receipt of large-scale IVD diagnostics kit orders from state governments.
• Expansion of the Baazar Style Retail network beyond 500 stores.
• Export margin trajectory under a favorable USD/INR exchange rate.

Time Horizon: Medium-term (3-12 months)

Industry Context

The global female condom market is estimated to reach USD 1.2 billion by 2030, presenting a massive growth opportunity for Cupid's newly certified premium nitrile variants. Domestically, the company is bridging the gap between clinical healthcare products and mainstream consumer wellness.

Key Risks to Watch

• FMCG scale-up is highly capital-intensive and may experience near-term margin pressure due to elevated advertising and promotional spend.
• The stock remains under the long-term Additional Surveillance Measure (ASM) framework on BSE and NSE, signaling heightened regulatory monitoring and trading volatility.
• Heavy reliance on international B2B procurement and government tenders makes revenues vulnerable to geopolitical disruptions or tender delays.

Recent Developments

Cupid reported record Q1 FY27 results on August 7, 2026, with consolidated net profit surging nearly threefold YoY to ₹44.15 crore. Promoter and CMD Aditya Kumar Halwasiya actively increased his personal stake to 33.45% through open-market purchases in mid-August 2026. Additionally, on July 29, 2026, Cupid deployed a follow-on investment of USD 5 million in GII Healthcare to expand its international distribution network.

Closing Insight

Cupid is entering a high-growth phase, fueled by robust global export dynamics and aggressive domestic expansion. While the ambitious targets reflect strong execution visibility, long-term investors must closely monitor premium valuation risks and the progress of its non-latex product lines.

High Performance Trading with SAHI.